The U.S. Meals and Drug Administration (FDA) has upgraded a recall of a generally prescribed thyroid treatment because of what it described as “subpotent” lively substances.
The recall of greater than 160,000 bottles of levothyroxine sodium, which went into impact June 20, was upgraded to a Class II recall on July 23. Class II remembers happen when use of the drug poses a average public well being danger, in keeping with the FDA.
The recall was initiated as a result of the treatment content material of the recalled tablets is “beneath the accepted specification,” in keeping with the New York-based tv community NTD.
No different particulars have been out there in regards to the recall, together with whether or not anybody has grow to be in poor health from the weak tablets.
Levothyroxine sodium is used to deal with a sluggish thyroid gland (hypothyroidism). Left untreated, hypothyroidism can result in coronary heart issues and excessive ldl cholesterol, amongst different points, in keeping with the Mayo Clinic..
The recalled medication are manufactured by India-based Intas Prescribed drugs for North Carolina-based Accord Healthcare, NTD reported. They whole 160,630 bottles and are available in numerous doses, strengths, and packages, together with:
- Lot D2400536; expiration date, Feb. 28, 2026
- Lot D2300325; expiration date, Jan. 31, 2026
- Lot D2400679; expiration date, Feb. 28, 2026
- Lot D2300087; expiration date, Dec. 31, 2025
- Lot D2300092; expiration date, Dec. 31, 2025
- Lot D2400722; expiration date, March 31, 2026
- Lot D2300104; expiration date, Dec. 31, 2025
- Lot D2300076; expiration date, Dec. 31, 2025
- Lot D2300042; expiration date, Dec. 31, 2025
Extra data:
Extra particulars on the recalled thyroid tablets could be discovered on the FDA’s web site.
Copyright © 2025 HealthDay. All rights reserved.
Quotation:
FDA upgrades recall on 160,000+ bottles of thyroid treatment (2025, July 24)
retrieved 24 July 2025
from https://medicalxpress.com/information/2025-07-fda-recall-bottles-thyroid-medication.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
